Category: Latest News
-
Stellantis Issues Recall for Nearly 164,000 Jeep Vehicles Over Door Trim Concerns
Stellantis (NYSE:STLA) has announced a recall of close to 164,000 Jeep vehicles in the U.S. due to a possible detachment of door trim, the U.S. National Highway Traffic Safety Administration reported Wednesday. The recall covers select Chrysler Jeep Wagoneer and Jeep Grand Wagoneer models produced between 2022 and 2025. The defect involves trim on both…
-
GSK and Eli Lilly Join $350 Billion U.S. Drug Investment Wave Amid Tariff Concerns
GSK (NYSE:GSK) and Eli Lilly (NYSE:LLY) announced new investments in U.S. manufacturing on Tuesday, joining a growing number of global pharmaceutical companies expanding domestic capacity as the Trump administration weighs tariffs on imported medicines. The Wall Street Journal first reported the trend, noting that more than a dozen drugmakers have committed over $350 billion in…
-
Eli Lilly to Seek Global Approval for Experimental Weight-Loss Drug
Eli Lilly (NYSE:LLY) is preparing to file for regulatory approval of its investigational weight-loss medication, orforglipron, in several key markets in rapid succession, according to the company’s international president, Patrik Jonsson. “We are submitting to most of the major regulatory bodies pretty much at the same time,” Jonsson told Reuters. The filings will target authorities…
-
Crude Steadies Near Two-Week High as Fed Decision Looms
Oil prices held steady in Asian markets Wednesday after surging in recent sessions on concerns over potential disruptions to Russian supply, as traders awaited the outcome of the U.S. Federal Reserve’s policy meeting. Brent futures for November edged down to $68.39 a barrel, while West Texas Intermediate was at $64.09 a barrel (21:48 ET /…
-
Gold dips from record highs as markets await Fed guidance
Gold prices pulled back slightly in Wednesday’s early Asian trading, with investors cautious ahead of the U.S. Federal Reserve’s interest rate decision and policy outlook scheduled later in the day. Spot gold was down 0.4% at $3,673.38 per ounce by 02:40 ET (06:40 GMT), after reaching a historic high of $3,702.95 on Tuesday. U.S. December…
-
Dow Jones, S&P, Nasdaq, Wall Street Futures, Markets Cautious Ahead of Fed Rate Decision; General Mills Earnings on Deck
U.S. stock futures were largely flat Wednesday as investors awaited a key Federal Reserve interest rate decision. While the majority of market participants expect a cut in borrowing costs, uncertainty remains over its size and the Fed’s broader economic outlook. Meanwhile, U.K. inflation stayed steady, and packaged foods leader General Mills (NYSE: GIS) is set…
-
STMicroelectronics to Invest $60 Million in Tours Facility Amid Reorganization
STMicroelectronics (NYSE:STM) has announced plans to invest $60 million in its Tours plant in France, aiming to establish a pilot line for cutting-edge semiconductor manufacturing. The Franco-Italian chipmaker said the investment will support the next phase of an advanced production process at the site. In recent months, the company has been relocating older chip production…
-
U.S. Stocks Close Slightly Lower Following Lackluster Trading Session
After ending the previous session mostly higher, stocks showed a lack of direction over the course of the trading day on Tuesday. The Nasdaq and the S&P 500 reached new record intraday highs in early trading but spent the rest of the day lingering near the unchanged line. The major averages eventually ended the day…
-
Warner Bros Discovery Shares Drop Amid Merger Uncertainty and Analyst Downgrade
Warner Bros Discovery (NASDAQ:WBD) saw its stock decline 8% as investors reacted to merger uncertainties and a recent analyst downgrade. CNBC’s David Faber reported that there “may be a bit of a longer wait” for Paramount Skydance to submit a bid for Warner Bros than initially expected, tempering investor optimism that had previously fueled gains…
-
Hims & Hers Stock Drops After FDA Issues Warning on Semaglutide Marketing
Shares of Hims & Hers Health Inc. (NYSE:HIMS) fell 8% Tuesday following a warning letter from the U.S. Food and Drug Administration concerning the company’s marketing claims related to its compounded semaglutide products. The FDA criticized the telehealth firm for making “false or misleading” statements on its website regarding compounded semaglutide offerings. Specific claims flagged…